P. Cohen

Molecular Biology · Biochemical Journal · 2000–2007

A researcher in the Science corpus: 12 papers; trusts 4 researchers and is trusted by 41 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 48 citations into it; #915 of 17,773 by trust here, #1,704 by citations
• Hematology — 9 citations into it
• Oncology — 5 citations into it; #1,622 of 1,698 by trust here, #786 by citations

Whom P. Cohen trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. S. Frame
2. Paul Polakis
3. Brian J. Druker
4. Thomas Bodenheimer
5. V. Lee

Who trusts P. Cohen overall

1. Lauren E Tebay
2. L. Meijer
3. Matthias Mann
4. D. Komander
5. B. Manning
6. R. Roskoski
7. Jeffrey A. Ubersax
8. H. Robertson
9. Yi Liu
10. W. Plaxton

Papers from P. Cohen's perspective

Ordered by how strongly the researchers P. Cohen trusts endorse each paper. Same corpus, a different order for every researcher.

1. The specificities of protein kinase inhibitors: an update. (Biochemical Journal)
2. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. (New England Journal of Medicine)
3. Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. (Molecules and Cells)
4. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. (Science)
5. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification (Science)
6. Abundant Tau Filaments and Nonapoptotic Neurodegeneration in Transgenic Mice Expressing Human P301S Tau Protein (Journal of Neuroscience)
7. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase (Proceedings of the National Academy of Sciences of the United States of America)
8. Specificity and mechanism of action of some commonly used protein kinase inhibitors
9. Role of AMP-activated protein kinase in mechanism of metformin action. (Journal of Clinical Investigation)
10. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR (Proceedings of the National Academy of Sciences of the United States of America)

Their papers

• A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. (2001) — 706 citations
• The regulation of protein function by multisite phosphorylation--a 25 year update. (2000) — 1,117 citations
• Protein kinases — the major drug targets of the twenty-first century? (2002) — 1,979 citations
• Specificity and mechanism of action of some commonly used protein kinase inhibitors. (2000) — 3,147 citations
• The specificities of protein kinase inhibitors: an update. (2003) — 1,434 citations
• GSK3 takes centre stage more than 20 years after its discovery. (2001) — 1,516 citations
• The selectivity of protein kinase inhibitors: a further update. (2007) — 2,647 citations
• The renaissance of GSK3 (2001) — 1,581 citations
• The origins of protein phosphorylation (2002) — 1,129 citations
• GSK3 inhibitors: development and therapeutic potential (2004) — 781 citations
• Glycogen Synthase from Rabbit Skeletal Muscle (2005) — 156 citations
• Specificity and mechanism of action of some commonly used protein kinase inhibitors (2000) — 1,611 citations